Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients

Conference Correspondent  - SABCS Highlights

Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer is associated with an increased clinical and economic burden. Brain metastases are linked to significantly worse outcomes. There are limited data on healthcare resource utilization among patients with HER2-positive metastatic breast cancer and brain metastases. Chiemeka Ike and colleagues used retrospective claims data to help describe therapeutic patterns and healthcare resource utilization among patients with HER2-positive metastatic breast cancer with or without brain metastases who received HER2-targeted therapy.

They used the IBM Watson HealthTM MarketScan commercial claims and Medicare Supplemental databases to extract patient data from July 2012 until December 2018. They used the data to assess patients with HER2-positive metastatic breast cancer.

Ike and colleagues described several demographic and clinical characteristics of this patient group, including treatment patterns by line of therapy and the presence or absence of brain metastases, and healthcare resource utilization. The study initiation (index) date was the first metastatic diagnosis. Measured overall and by brain metastases compared with non-brain metastases were healthcare resource utilization outcomes per patient per year in the follow-up period after metastatic diagnosis. These healthcare resource utilization outcomes included emergency department services, outpatient services, inpatient services, and total length of stay.

The study included 4509 patients. A total of 4406 patients had no evidence of brain metastases at index, and 103 (2.3%) patients had brain metastases. Following study initiation 590 (13.1%) patients developed brain metastases.

At index, the mean age was 53.7 years. Overall median follow-up time was 23.2 months. Median time on treatment measured in months was 7.6, 7.2, and 6.2 for first-line, second-line, and third-line therapy, respectively.

Across all lengths of stay, trastuzumab-based regimens were most used. In first-line treatment, trastuzumab emtansine use was 0.9%. In second-line and third-line treatment, trastuzumab emtansine use was 9.7% and 13.0%, respectively. Trastuzumab emtansine was also used more in patients with brain metastases than in patients without brain metastases: in first-line (2.4% vs 0.9%), second-line (22.6% vs 7.7%), and third-line (25% vs 10.1%).

Overall, there was a range of lapatinib use extending from 1.6% in first-line treatment to 8.3% in third-line. Patients with brain metastases more frequently used lapatinib when compared with patients with non-brain metastases (first-line: 11.8% vs 1.2%; second-line: 20.5% vs 1.8%; third-line: 21.2% vs 5.1%).

Per patient per year, the mean number of inpatient services was higher for patients with brain metastases (1.2 patients compared with 0.5 patients without brain metastases). The average total length of stay of patients with brain metastases was 8.6 days versus 2.6 days when compared with patients with non-brain metastases. The average number of emergency department visits of patients with brain metastases was 2.5 compared with 1.2 without brain metastases. The mean number of outpatient services was 56.9; however, there was no difference in the number of outpatient services between brain metastases patients.

The authors concluded that among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of patients with brain metastases is significantly higher when compared with patients without brain metastases. This underscores the critical need for systemic therapies that are effective and improve outcomes and decrease the burden of disease, particularly the healthcare system burden for patients with HER2-positive metastatic breast cancer, especially those with brain metastases.

Source: Ike C, Schwartz N, Surinach A, et al. Real world treatment patterns and healthcare resource utilization among HER2+ metastatic breast cancer patients with and without brain metastases: a retrospective cohort study. Presented at: 2020 San Antonio Breast Cancer Symposium, December 8-11, 2020. Abstract PS14-15.

Related Items
Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Conference Correspondent  published on December 8, 2017 in SABCS Highlights
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: